CSIMarket
 
Neximmune Inc   (NEXI)
Other Ticker:  
 
 
Price: $5.7900 $-0.26 -4.298%
Day's High: $6.23 Week Perf: -2.85 %
Day's Low: $ 5.79 30 Day Perf: -35.38 %
Volume (M): 31 52 Wk High: $ 28.69
Volume (M$): $ 178 52 Wk Avg: $6.64
Open: $6.10 52 Wk Low: $1.25



 Market Capitalization (Millions $) 6
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -44
 Cash Flow (TTM) (Millions $) -37
 Capital Exp. (TTM) (Millions $) 0

Neximmune Inc
Neximmune Inc is a biotechnology company that specializes in developing novel immunotherapies for the treatment of various diseases. The company focuses on next-generation T-cell therapies to harness the power of the immune system to target and eliminate cancer cells. Neximmune's platform technology utilizes the body's natural defense mechanisms to create personalized therapies that are specifically tailored to each patient. By leveraging their expertise in molecular immunology, the company aims to revolutionize the field of immunotherapy and provide innovative treatment options for patients.


   Company Address: 9119 Gaither Road Gaithersburg, 20877 MD
   Company Phone Number: 825-9810   Stock Exchange / Ticker: NASDAQ NEXI
   NEXI is expected to report next financial results on March 27, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Financing Agreement

NexImmune's Financial Dilemma: High Leverage Ratio Despite Successful Offerings

Published Tue, Feb 6 2024 9:43 PM UTC


NexImmune's Tangible Leverage Ratio Reaches New All-Time High Despite Borrowings
NexImmune recently announced the closing of a $3.67 million registered direct offering priced at-the-market under Nasdaq rules. This comes at a time when the company's Tangible Leverage Ratio has deteriorated to 0.76 in the third quarter of 2023, reaching a new all-time high.
In com...

Shares

NexImmune's Registered Direct Offering Positions Company for Further Growth and Development

Published Fri, Feb 2 2024 7:00 PM UTC


In an exciting move that reflects the ongoing progress and potential of NexImmune Inc, the company has recently announced a registered direct offering priced at-the-market under Nasdaq rules. The offering, totaling $3.67 million, signifies a significant step forward for NexImmune as it seeks to leverage its innovative immunotherapy platform to address unmet medical need...

Neximmune Inc

Neximmune Inc. Surpasses Industry Expectations as Operating Loss Narrows in Q3 of 2023


As a biotechnology company operating in the Major Pharmaceutical Preparations industry, Neximmune Inc is an emerging player in the field of immunotherapy. While larger companies dominate the headlines, it is important to pay attention to the smaller businesses that are also making significant strides. Recently, Neximmune Inc revealed its financial results for the third quarter of 2023, which portray a promising picture of the company's performance.
One key highlight from the report is that Neximmune Inc reported an operating loss of $-9.995767 million for the third quarter of 2023. While operating losses are never ideal, it is important to note that this figure represents a significant improvement compared to the same period in 2022, where the operating loss stood at $-14.856101 million. This impressive reduction in operating loss showcases the company's dedication to cost optimization and signifies a positive direction for Neximmune Inc.

Neximmune Inc

Neximmune Inc Reports Decreased Operating Loss in Q2, Showing Positive Trend Towards Financial Stability

Neximmune Inc Reports Operating Loss in Q2 but Shows Improvement
Neximmune Inc, a leading company in the industry, recently released its financial report for the April to June 2023 reporting season at the NEXI. Shareholders were disappointed to learn that no significant improvements were made in revenue during this period. However, there is still some good news to be found in the report. The company showed a decrease in operating loss, which stood at $-7.784659 million, compared to $-15.925964 million in the same period last year.
This improvement in operating loss has gained the attention and affirmation of countless market observers, who believe that Neximmune Inc is on track to become a prominent player in the industry. Furthermore, the deficit has significantly reduced to $-7.567 million, from $-15.861 million in the second quarter of 2022. This positive trend indicates that Neximmune Inc is moving in the right direction towards financial stability.

Neximmune Inc

Neximmune Inc Shows Promising Progress, Reducing Operating Shortfall by 36% in Q1 2023

Investors were pleasantly surprised by the recent developments in the stock market as Neximmune Inc underwent unexpected changes at the top-line during the earnings cycle of fiscal January to March 31, 2023. While the stockholders did not anticipate any surprises, the company managed to work more efficiently, bringing its operating shortfall down to $-9.825409 million from $-15.053522 million during the same period last year.
This progression has certainly caught the attention of investors who have been closely monitoring Neximmune's operating shortfall over the past year. The fact that the deficit has declined to $-9.565 million from $-15.023 million in the first quarter of 2022 is a positive development for the firm on its path to become a doyen in the Healthcare sector.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com